Exploration of Asthma & Allergy

Table 4. Aspirin forms and doses used in different aspirin provocation tests.

Provocation method	Aspirin form	Starting dose	Dose escalation	Maximum/Cumulative dose	Typical provocative dose
OAPT	ASA capsule or tablet	20–40 mg (5 mg in high-risk patients)	Gradual increase every 60–90 minutes	Final single dose 160–325 mg; cumulative dose ~340–545 mg	Usually 60–80 mg
NAPT	L-ASA solution (alternative: ketorolac)	2–5 mg ASA equivalent	1–4 incremental doses	Standard 18–20 mg; extended protocols up to 70 mg	Typically 10–20 mg
BAPT	L-ASA via nebulizer	0.18 mg	Incremental cumulative doses every 30 minutes	182 mg ASA equivalent	Often 1–10 mg
IAPT	ASA (IV formulation)	Protocol-dependent	Slow infusion or bolus according to protocol	Protocol-dependent	May be positive at low doses

Return to article view

OAPT: oral aspirin provocation test; NAPT: nasal aspirin provocation test; BAPT: bronchial aspirin provocation test; IAPT: intravenous aspirin provocation test; L-ASA: L-lysine acetylsalicylate; ASA: acetylsalicylic acid.

Declarations

Author contributions

NOA: Conceptualization, Investigation, Writing—original draft. GEÇ: Conceptualization, Investigation, Writing—review & editing, Supervision. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011;66:818–29. [DOI] [PubMed]

Woo SD, Luu QQ, Park HS. NSAID-Exacerbated Respiratory Disease (NERD): From Pathogenesis to Improved Care. Front Pharmacol. 2020;11:1147. [DOI] [PubMed] [PMC]

Andersén H, Ilmarinen P, Honkamäki J, Tuomisto LE, Hisinger-Mölkänen H, Backman H, et al. NSAID-exacerbated respiratory disease: a population study. ERJ Open Res. 2022;8:00462-2021. [DOI] [PubMed] [PMC]

Makowska JS, Burney P, Jarvis D, Keil T, Tomassen P, Bislimovska J, et al. Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA²LEN) survey. Allergy. 2016;71:1603–11. [DOI] [PubMed]

Li KL, Lee AY, Abuzeid WM. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management. Med Sci (Basel). 2019;7:45. [DOI] [PubMed] [PMC]

Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135:676–81.e1. [DOI] [PubMed]

Romano A, Valluzzi RL, Alvarez-Cuesta E, Ansotegui I, Asero R, Barbaud A, et al.; Review Panel Members. Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement. World Allergy Organ J. 2025;18:101086. [DOI] [PubMed] [PMC]

Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999;104:5–13. [DOI] [PubMed]

Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025–9. [DOI] [PubMed]

10.

Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245–52. [DOI] [PubMed] [PMC]

11.

Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:1407–15. [DOI] [PubMed] [PMC]

12.

Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1999;160:291–6. [DOI] [PubMed]

13.

Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16:432–6. [DOI] [PubMed]

14.

Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89:474–8. [DOI] [PubMed]

15.

Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123:406–10. [DOI] [PubMed]

16.

Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol. 2014;133:98–103.e1. [DOI] [PubMed]

17.

Celejewska-Wójcik N, Wójcik K, Ignacak-Popiel M, Ćmiel A, Tyrak K, Gielicz A, et al. Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis. Allergy. 2020;75:831–40. [DOI] [PubMed] [PMC]

18.

Scott WC, Cahill KN, Milne GL, Li P, Sheng Q, Huang LC, et al. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147:1318–28.e5. [DOI] [PubMed] [PMC]

19.

Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019;74:28–39. [DOI] [PubMed]

20.

Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111–8. [DOI] [PubMed]

21.

Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100:420–5. [DOI] [PubMed]

22.

Ortega N, Doña I, Moreno E, Audicana MT, Barasona MJ, Berges-Gimeno MP, et al. Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol. 2014;24:308–23. [PubMed]

23.

Melillo G, Balzano G, Bianco S, Dahlén B, Godard P, Kowalsky ML, et al. Report of the INTERASMA Working Group on Standardization of Inhalation Provocation Tests in Aspirin-induced Asthma. Oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy. 2001;56:899–911. [DOI] [PubMed]

24.

Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017;5:537–45. [DOI] [PubMed]

25.

Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol. 1980;66:82–8. [DOI] [PubMed]

26.

Pelletier T, Roizen G, Ren Z, Hudes G, Rosenstreich D, Jerschow E. Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7:1319–21. [DOI] [PubMed]

27.

Chen JR, Buchmiller BL, Khan DA. An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2015;3:926–31.e1. [DOI] [PubMed]

28.

DeGregorio GA, Singer J, Cahill KN, Laidlaw T. A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2019;7:1174–80. [DOI] [PubMed] [PMC]

29.

Morales DR, Guthrie B, Lipworth BJ, Jackson C, Donnan PT, Santiago VH. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015;70:828–35. [DOI] [PubMed]

30.

Koh YI, Yu JE, Sim DW. Cross-Reactive NSAID Hypersensitivity: Clinical Findings From Aspirin Provocation and Alternative Drug Challenge Testing. Clin Transl Sci. 2025;18:e70335. [DOI] [PubMed] [PMC]

31.

Nizankowska E, Bestyńska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000;15:863–9. [DOI] [PubMed]

32.

Bentabol-Ramos G, Saenz de Santa Maria-Garcia R, Vidal-Diaz M, Eguiluz-Gracia I, Testera-Montes A. The Utility of Nasal Challenges to Phenotype Asthma Patients. Int J Mol Sci. 2022;23:4838. [DOI] [PubMed] [PMC]

33.

Izquierdo-Domínguez A, Bobolea I, Doña I, Campo P, Segura C, Ortega N, et al.; SEAIC Rhinoconjunctivitis Committee. Statement of the Spanish Society of Allergology and Clinical Immunology on Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol. 2020;30:1–13. [DOI] [PubMed]

34.

Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105:130–5. [DOI] [PubMed]

35.

Alonso-Llamazares A, Martinez-Cócera C, Domínguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy. 2002;57:632–5. [DOI] [PubMed]

36.

Xiao H, Xu F, Jia Q, Zhang L, Shi C, Du J, et al. Intranasal Aspirin Challenge for Diagnosis of Aspirin-Exacerbated Respiratory Disease: Symptom Score Criteria and Optimal Dosage. J Allergy Clin Immunol Pract. 2025;13:1732–8. [DOI] [PubMed]

37.

Barranco P, Bobolea I, Larco JI, Prior N, López-Serrano MC, Quirce S. Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study. J Investig Allergol Clin Immunol. 2009;19:446–52. [PubMed]

38.

Seong GM, Lee J, Kim C. Intravenous aspirin challenge as a diagnosis of nonsteroidal anti-inflammatory drugs hypersensitivity. Asian Pac J Allergy Immunol. 2020;38:124–8. [DOI] [PubMed]

39.

Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K. Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy. 2004;34:1262–9. [DOI] [PubMed]

40.

Eraso I, Sangiovanni S, Morales EI, Fernández-Trujillo L. Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: A systematic review of the literature and meta-analysis. PLoS One. 2021;16:e0247871. [DOI] [PubMed] [PMC]

41.

Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol. 1998;101:581–6. [DOI] [PubMed]

42.

Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;94:652–7. [DOI] [PubMed]

43.

Bobolea I, Rubira N, Mullol J. Respiratory Exposure Tests in Aspirin Exacerbated Respiratory Disease. Curr Treat Options Allergy. 2023;10:255–66. [DOI]

44.

Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146:595–605. [DOI] [PubMed]

45.

Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K, et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1585–7.e4. [DOI] [PubMed]

46.

Laidlaw TM, Mullol J, Fan C, Zhang D, Amin N, Khan A, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7:2462–5.e1. [DOI] [PubMed]

47.

White AA, Bosso JV, Stevenson DD. The clinical dilemma of “silent desensitization” in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2013;34:378–82. [DOI] [PubMed]